Wealthspire Advisors (New York)’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Wealthspire Advisors (New York)’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235K	Buy	2,377 +1	+0%	+$90	﹤0.01%	1104
2026 Q1	$206K	Buy	2,376 +1	+0%	+$88	﹤0.01%	857
2025 Q4	$201K	Buy	2,375 +3	+0.1%	+$239	﹤0.01%	972
2025 Q3	$172K	Buy	+2,372	New	+$164K	﹤0.01%	846

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return

Wealthspire Advisors (New York)'s IHE Position: Q2 2026 in Review

Wealthspire Advisors (New York) increased its iShares US Pharmaceuticals ETF (IHE) stake by 0.04% in Q2 2026, buying an estimated $90 and bringing the position to 2,377 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Wealthspire Advisors (New York) first reported a position in IHE in Q3 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Wealthspire Advisors (New York) held 2,377 shares of iShares US Pharmaceuticals ETF worth $235K as of Q2 2026.
Wealthspire Advisors (New York) bought 1 iShares US Pharmaceuticals ETF share in Q2 2026, an estimated $90.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #1104 holding.
Wealthspire Advisors (New York) first reported a position in iShares US Pharmaceuticals ETF in Q3 2025 and has held it in 4 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.